AdaptHealth Corp. (AHCO) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers AdaptHealth Corp.'s quarterly report on Form 10-Q for the period ended September 30, 2025. AdaptHealth is a national provider of home medical equipment (HME), supplies, and services, operating through four segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. The company services approximately 4.3 million patients annually across 47 states.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Revenue | $820.3 million | $805.9 million | $2,398.6 million | $2,404.3 million |
| Net Income (Attributable to AHCO) | $24.5 million | $22.9 million | $32.0 million | $40.2 million |
| Diluted EPS | $0.16 | $0.15 | $0.21 | $0.27 |
| Adjusted EBITDA | $170.1 million | $164.3 million | $453.5 million | $488.1 million |
| Operating Cash Flow (YTD) | $418.6 million (2025) vs $391.4 million (2024) | |||
| Free Cash Flow (YTD) | $140.1 million (2025) vs $162.7 million (2024) | |||
| Cash & Equivalents | $80.4 million (as of Sept 30, 2025) | |||
| Total Debt (Principal) | $1,775.0 million ($325M Term Loan + $1,450M Senior Notes) |
Material Changes vs. Prior Period
- Revenue Drivers: Q3 2025 revenue increased 1.8% year-over-year, driven by organic growth of 5.1% and acquisitions of 1.0%, partially offset by a 4.3% decline due to dispositions. YTD revenue was flat (-0.2%) due to significant disposition impacts (-2.5%).
- Segment Performance:
- Sleep Health: Revenue up 5.7% (Q3) and 1.3% (YTD) due to higher patient census for CPAP resupply.
- Respiratory Health: Revenue up 7.8% (Q3) and 5.6% (YTD) driven by oxygen equipment census.
- Diabetes Health: Revenue up 6.4% (Q3) but down 2.1% (YTD) due to a shift in payor mix from commercial to government.
- Wellness at Home: Revenue down 16.0% (Q3) and 7.6% (YTD) primarily due to the disposition of two businesses in Q2 2025.
- Profitability: Adjusted EBITDA margin improved to 20.7% in Q3 2025 from 20.4% in Q3 2024. However, YTD Adjusted EBITDA margin decreased to 18.9% from 20.3% in 2024, impacted by the gain on sale of businesses in the prior year and higher non-recurring expenses in the current year.
- Disposals: The company recognized a pre-tax gain of $32.2 million in YTD 2025 from the sale of two Wellness at Home businesses, resulting in a discrete income tax expense of $27.4 million.
- Cost Structure: Cost of net revenue increased 2.3% in Q3 2025, driven by higher patient equipment depreciation (due to accelerated depreciation on respiratory equipment) and inflationary labor costs.
Guidance, Outlook, Risks, and Unusual Items
- Capital Allocation: The company made voluntary repayments of $212.8 million on its 2024 Term Loan during the first nine months of 2025. As of September 30, 2025, $325.0 million remains outstanding on the Term Loan, and there were no borrowings under the $300 million Revolver.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 resulted in a $32.7 million current income tax receivable due to reinstated bonus depreciation and favorable interest deduction limitations.
- Legal Proceedings:
- Class Action Settlement: The company reached an agreement in principle to settle the Allegheny County Consolidated Class Action (alleging billing practices and compliance issues). The settlement is expected to be funded primarily by insurance carriers and is subject to court approval.
- Government Investigations: The company is cooperating with False Claims Act investigations regarding ventilator billing (SDNY - closed in August 2025 with no intent to pursue), humidifier billing (South Carolina), and respiratory device billing (Pennsylvania).
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective due to a continuing material weakness in inventory valuation. Management is implementing a perpetual inventory system to remediate this issue.
- Reclassifications: The company reclassified revenue cycle management costs from Cost of Net Revenue to General and Administrative expenses to align with industry practice, impacting period-over-period comparability of expense line items.
Investor Verification Checklist
- Inventory Valuation Weakness: Verify the progress of the perpetual inventory system implementation and the effectiveness of the interim quarterly controls designed to mitigate the material weakness.
- Legal Settlement Terms: Monitor the finalization and court approval of the Allegheny County class action settlement to confirm the actual cash outflow and insurance coverage.
- Disposition Impact: Assess the long-term revenue impact of the Wellness at Home segment divestitures and the sustainability of organic growth in Sleep and Respiratory segments.
- Debt Covenants: Confirm continued compliance with the Consolidated Total Leverage Ratio and Interest Coverage Ratio covenants under the 2024 Credit Agreement, especially given the variable interest rate exposure.
- Payor Mix Shifts: Evaluate the margin implications of the ongoing shift from commercial to government payors in the Diabetes Health segment.